Immuneering Corp
Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Immuneering Corp's stock with a target price of $15.2, indicating strong growth potential.
Financial Health
Immuneering Corp is maintaining a solid cash flow and reasonable book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring IMRX
Garage Innovators
Meet the companies that are inventing tomorrow, today. These stocks represent businesses with exceptional in-house research and development, carefully selected by professional analysts for their ability to create breakthrough products and technologies from within.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Research-driven focus
The company’s value depends on scientific and clinical progress; milestones can create upside but outcomes are uncertain.
Catalysts to watch
Clinical readouts, regulatory news and partnerships often drive price moves — though results can be binary and unpredictable.
Small-cap dynamics
With a market cap near $337m, liquidity and financing needs matter; smaller market caps can amplify gains and losses.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
